Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kappaproct add-on therapy in treatment-refractory ulcerative colitis (placebo-controlled)
2011-003130-14Phase 3Completed
- Sponsor
- InDex Pharmaceuticals
- Start
- Aug 2011
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in autoimmune colitis comparing Kappaproct add-on with Placebo add-on (2 arms). Primary endpoint: Clinical remission at week 12. Started Aug 2011; status: completed.
02
Drugs
cobitolimod
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2011-003130-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003130-14.